Antech launches breakthrough in-hospital innovation, Nu.Q® Canine Cancer Test
ORLANDO, Fla., Jan. 12, 2024 /PRNewswire/ -- Antech, the veterinary diagnostics company focused on helping veterinary professionals predict, diagnose and monitor wellness and disease, today announced it will launch the breakthrough in-hospital Nu.Q® Canine Cancer Test at this year's annual VMX meeting.
- ORLANDO, Fla., Jan. 12, 2024 /PRNewswire/ -- Antech, the veterinary diagnostics company focused on helping veterinary professionals predict, diagnose and monitor wellness and disease, today announced it will launch the breakthrough in-hospital Nu.Q® Canine Cancer Test at this year's annual VMX meeting.
- Nu.Q ® is a breakthrough technology that measures circulating nucleosomes, supporting earlier cancer detection in some of the most prevalent types of canine cancers.
- To learn more about the in-hospital Nu.Q ®, visit booth 1522 at VMX 2024 or speak to your local Antech representative.
- The Nu.Q® Canine Cancer Test is supplied to Antech's Heska affiliate under license by Belgian Volition SRL.